ALDX (Aldeyra Therapeutics) Accounts Payable: $0.14 Mil (As of Mar. 2026)

What is Aldeyra Therapeutics Accounts Payable?

Aldeyra Therapeutics ALDX +10.81% 29 Accounts Payable is $0.14 Mil as of Mar. 2026. GuruFocus rates ALDX with a GF Score™ of 29/100. The stock has 2 warning signs investors should review.

Aldeyra Therapeutics's Accounts Payable for the quarter that ended in Mar. 2026 was $0.14 Mil.

Aldeyra Therapeutics's quarterly Accounts Payable increased from Sep. 2025 ($0.01 Mil) to Dec. 2025 ($0.16 Mil) but then declined from Dec. 2025 ($0.16 Mil) to Mar. 2026 ($0.14 Mil).

Aldeyra Therapeutics's annual Accounts Payable declined from Dec. 2023 ($1.34 Mil) to Dec. 2024 ($0.18 Mil) and declined from Dec. 2024 ($0.18 Mil) to Dec. 2025 ($0.16 Mil).

Aldeyra Therapeutics Accounts Payable Related Terms

Aldeyra Therapeutics Accounts Payable Historical Data

* Premium members only.

The historical data trend for Aldeyra Therapeutics's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aldeyra Therapeutics Accounts Payable Chart

Aldeyra Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Accounts Payable

Get a 7-Day Free Trial

1.02

0.13

1.34

0.18

0.16

Aldeyra Therapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Accounts Payable	Get a 7-Day Free Trial															0.35	1.46	0.01	0.16	0.14

29GF Score

Aldeyra Therapeutics Inc ALDX

Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Aldeyra Therapeutics Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →

What does a Accounts Payable of $0.14 Mil mean?

Aldeyra Therapeutics (ALDX) has a Accounts Payable of $0.14 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Aldeyra Therapeutics and its competitors.

Is Aldeyra Therapeutics' Accounts Payable too high?

Aldeyra Therapeutics' current Accounts Payable is $0.14 Mil. Overall, Aldeyra Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.

How does Aldeyra Therapeutics' Accounts Payable compare to ONCY and VRCA?

Aldeyra Therapeutics' Accounts Payable of $0.14 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Accounts Payable for a Biotechnology company?

A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Accounts Payable mean?

A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Aldeyra Therapeutics and its competitors. Aldeyra Therapeutics's current Accounts Payable is $0.14 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Aldeyra Therapeutics stock overvalued right now?

Aldeyra Therapeutics (ALDX) has a current Accounts Payable of $0.14 Mil. The current Accounts Payable is $0.14 Mil. Aldeyra Therapeutics' overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Accounts Payable calculated?

Accounts Payable is calculated from a company's financial statements. For Aldeyra Therapeutics (ALDX), the current Accounts Payable is $0.14 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aldeyra Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies ONCY VRCA CUE ALPS ENGN PEPG NTHI GUTS AARD KLRS VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges 137:Germany

Address 131 Hartwell Avenue, Suite 320, Lexington, MA, USA, 02421

Website https://www.aldeyra.com

Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.

29GF Score

Get the complete analysis for ALDX

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.05

Price

View ALDX Analysis

See Accounts Payable data for all stocks →